A U.S.-based venture capital firm invests in early-stage neuropsychiatric and mental health opportunities. The firm primarily invests from Pre-Seed through Series A, with initial checks typically ranging from $50K–$1M and capacity for follow-on investment. The firm is comfortable serving as the first institutional investor and can lead or co-invest alongside other investors. Investments may be structured through traditional equity financings or SAFEs. The firm primarily targets U.S.-based companies while remaining open to opportunities globally.
The firm invests in therapeutics and technologies addressing neuropsychiatric conditions, mental health, and general wellness. Areas of interest include psychedelic medicine, brain-computer interfaces, therapeutic platforms, precision diagnostics, and other technologies addressing neurological and psychiatric conditions. For biotechnology and therapeutics opportunities, the firm generally prefers assets that are at or approaching the IND stage. For medical technology opportunities, the firm is comfortable engaging earlier in the development process.
From a company and management team perspective, the firm does not impose strict requirements regarding team composition. The firm has a strong preference for founders with prior pharmaceutical or biotechnology industry experience or a demonstrated track record of successful entrepreneurship. The firm may seek a board seat or observer position on a case-by-case basis and takes a flexible approach to governance depending on the company’s stage and financing structure.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
